ALEC
Alector, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.95
+5.98%Year over year
Reported trailing growth
- Revenue
- -82.9%
- EBITDA
- +6.2%
- EBIT
- +6.0%
- EPS
- +6.1%
- Free cash flow
- +26.7%
- Operating cash flow
- +26.6%
Forward estimates
Based on analyst estimates
- Revenue
- -42.6%
- EBITDA
- +2.2%
- EPS
- +51.1%
Three-year CAGR
- Revenue
- -46.0%
- EBITDA
- -20.9%
- EBIT
- -0.6%
- Net income
- -20.1%
- EPS
- -13.0%
- Free cash flow
- +20.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026